Active Ingredient History
Brolucizumab sold under trade name Beovu among others, is a humanized single-chain antibody fragment for the treatment of neovascular (wet) age-related macular degeneration (AMD). Wikipedia
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Wet Macular Degeneration (approved 2019)
Choroidal Neovascularization (Phase 3)
Diabetes Mellitus (Phase 3)
Diabetic Retinopathy (Phase 3)
Eye Diseases (Phase 4)
Macular Degeneration (Phase 4)
Macular Edema (Phase 3)
Polypoidal Choroidal Vasculopathy (Phase 3)
Retinal Degeneration (Phase 4)
Retinal Diseases (Phase 4)
Retinal Dystrophies (Phase 4)
Retinal Vein Occlusion (Phase 3)
Wet Macular Degeneration (Phase 4)
Trial | Phase | Start Date | Organizations | Indications |
---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue